Status:
NOT_YET_RECRUITING
Evaluation of the Effectiveness of a Spa Treatment for People With Post-Covid 19 Conditions.
Lead Sponsor:
Central Hospital, Nancy, France
Conditions:
Post COVID-19 Condition
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Following the acute phase of Covid-19, some patients experience persistent or recurrent symptoms. These symptoms can take a number of forms: intense fatigue, cognitive dysfunction, respiratory difficu...
Detailed Description
Justification/context Most of the studies initially published involved cohorts of patients hospitalized during the initial phase. The French Covid-19 cohort, which studied 1137 patients after hospita...
Eligibility Criteria
Inclusion
- Person who has received full information about the organisation of the research, who has not
- to their participation and the use of their data, and who have given their free and free and informed consent in writing,
- Patients aged 18 and over,
- Patients with a history of symptomatic Covid-19 infection documented by RTPCR, antigenic test, positive serology in a patient not previously vaccinated or other virological diagnostic test validated at the patient's inclusion date,
- A person who has not required hospitalisation for treatment in the initial phase of Covid-19,
- Person presenting at least two common symptoms of the post-Covid condition from among fatigue, breathlessness, cognitive dysfunction, appearing de novo and evolving for more than for more than 12 weeks and present for more than 8 weeks,
- Initial and prolonged symptoms not explained by another diagnosis with no known link to with Covid-19,
- Normal SpO2 at rest not decreasing beyond 4% on exercise,
- Membership of a social security scheme or beneficiary of such a scheme.
Exclusion
- Acute cardiovascular disease (acute coronary syndrome, arrhythmia, heart failure, venous thromboembolism venous thromboembolic disease, myocarditis, stroke, acute ischaemia, etc.) less than stroke, acute ischaemia, etc.) less than 3 months old and at risk of recurrence or decompensation,
- Respiratory disease: COPD, interstitial fibrosis, exercise-induced desaturation, sleep apnoea
- Stroke less than 6 months old,
- Pregnant women,
- Adults subject to a legal protection measure (guardianship, curatorship, safeguard of justice),
- Serious and unstable psychiatric pathology, severe depressive syndrome, delirious decompensation, panic attacks, anxiety-depression syndrome,
- Acute and progressive conditions (infectious, cancerous and inflammatory),
- Person with a contraindication to hydrokinesitherapy and crenotherapy crenotherapy (infected dermatoses, severe immune deficiencies, inflammatory diseases, faecal or urinary incontinence, presence of a suprapubic or intravenous catheter, colostomy, hydrophobia)
- Refusal to sign the free and informed consent form
Key Trial Info
Start Date :
October 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06570239
Start Date
October 1 2024
End Date
October 1 2026
Last Update
August 26 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.